On Tuesday, Shares of Sprint Corp (NYSE:S), gained 0.11% to $4.43.
DA Davidson initiates coverage on Sprint Corporation (NYSE:S). In the latest research report, DA Davidson declares the target price to $4.5 per share on the shares. According to the latest information available, the shares are now rated Neutral by the analysts at the agency. The rating by the firm was issued on October 1, 2015.
Sprint Corporation is a holding company. The Company, along with its subsidiaries is a wireless communications company offering a range of wireless and wireline communications products and services.
Shares of Exelixis, Inc. (NASDAQ:EXEL), declined -2.03% to $5.78, during its last trading session.
Exelixis, declared positive overall survival (OS) results from coBRIM, the phase 3 pivotal trial evaluating cobimetinib, a specific MEK inhibitor discovered by Exelixis, in combination with vemurafenib in formerly untreated patients with unresectable locally advanced or metastatic melanoma carrying a BRAF V600 mutation. Exelixis’ collaborator Genentech, a member of the Roche Group, informed the company that coBRIM met its secondary endpoint of demonstrating a statistically noteworthy and clinically meaningful improvement in overall survival for patients receiving the combination of cobimetinib and vemurafenib, as contrast to vemurafenib monotherapy. Ongoing study monitoring did not identify any new safety signals. Long-term safety data are predictable later this year. These data will be the subject of a presentation at an forthcoming medical meeting.
Exelixis declared the first regulatory approval of cobimetinib in Switzerland in August 2015. U.S. and EU regulatory applications sponsored by Genentech and Roche, respectively, are presently under review. In the United States, the Prescription Drug User Fee Act action date is November 11, 2015. In the EU, Roche anticipates a regulatory decision by the end of this year following a positive opinion from the European Committee for Medicinal Products for Human Use declared in late September.
Exelixis Inc. is a biopharmaceutical company. The Company is engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing on resources development and commercialization of COMETRIQ (cabozantinib) for the treatment of progressive, metastatic medullary thyroid cancer (MTC) in the United States.
Shares of Amgen, Inc. (NASDAQ:AMGN), declined -1.79% to $141.22, during its last trading session.
Amgen declared that Express Scripts will provide access to Repatha™ (evolocumab) through its national formulary.
Repatha, approved by the U.S. Food and Drug Administration on Aug. 27, is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD), who require additional lowering of low-density lipoprotein cholesterol (LDL-C); and as an adjunct to diet and other LDL-lowering therapies for the treatment of patients with homozygous familial hypercholesterolemia (HoFH), who require additional lowering of LDL-C. The effect of Repatha on cardiovascular morbidity and mortality has not been determined.
In Phase 3 trials, adding Repatha to background lipid-lowering therapy that comprised statins resulted in intensive reductions in LDL-C levels with favorable effects on other lipid parameters. In patients with clinical ASCVD or HeFH, Repatha reduced LDL-C by about 54 to 77 percent contrast with placebo.1 In a pivotal Phase 3 trial, 90 percent of clinical ASCVD patients who received Repatha in addition to maximum doses of statins achieved a LDL-C level less than 70 mg/dL. In patients with HoFH, Repatha reduced LDL-C by about 30 percent contrast with placebo. Elevated LDL-C is an abnormality of cholesterol and/or fats in the blood.3,4 In the U.S., there are about 11 million people with ASCVD and/or familial hypercholesterolemia (FH), who have uncontrolled levels of LDL-C over 70 mg/dL, despite treatment with statins or other cholesterol-lowering therapies.2,5 Familial hypercholesterolemia is caused by genetic mutations that lead to high levels of LDL-C at an early age.6 It is estimated that one million people in the U.S. have FH (heterozygous and homozygous forms), yet less than one percent are diagnosed.7
Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering, developing, manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States, it sells its products to pharmaceutical wholesale distributors.
Finally, Infinera Corp. (NASDAQ:INFN), ended its last trade with -1.68% loss, and closed at $20.51.
Infinera introduced a new unified Intelligent Transport Network product portfolio to address the surge in demand forecast for metro 100 gigabit per second (Gb/s) packet-optical networking solutions in 2016. Mobile, video and cloud-based services are driving a transformation of metro packet-optical networks from 10 Gb/s to 100 Gb/s, and industry analysts forecast a surge in demand for metro 100 Gb/s in 2016. The new portfolio unifies Infinera’s long-haul DTN-X platforms with metro packet-optical solutions obtained through the acquisition of Transmode and introduces three new platforms to the DTN-X Family, enabling the company to address the entire wavelength division multiplexing (WDM) market from long-haul to metro access. IHS Research forecasts the end-to-end WDM market will top $15 billion by 2019.
New Unified Packet-Optical Portfolio
Infinera introduced new hardware and software capabilities that unify Infinera’s award winning long-haul DTN-X Family with the Infinera TM-Series metro packet-optical solution. The TM-Series joined the Infinera Intelligent Transport Network portfolio through the company’s acquisition of Transmode, a leading provider of metro packet-optical networks. New hardware modules for the DTN-X XTC Series enable direct 100 Gb/s WDM line-side interworking with the TM-Series. The TM-Series offers packet-optical transport for a rich set of metro applications counting mobile fronthaul and backhaul, business Ethernet and triple play aggregation for cable and service provider networks. The new PT-Fabric for the TM-Series is designed to extend these capabilities to terabit switching and metro 100 Gb/s networking.
Infinera introduced new capabilities for the Infinera Digital Node Administrator (DNA) network administration system, enabling unified control of the DTN-X Family and the TM-Series from metro access to long-haul core. The unified end-to-end portfolio is designed with extensive software defined network (SDN) programmability.
Infinera Corporation is engaged in optical transport networking systems. The Company provides optical transport networking equipment, software and services to Tier 1 and Tier 2 telecommunications service providers, Internet content providers (ICPs), cable operators, wholesale and enterprise carriers, research and education institutions and government entities around the world.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
